Kaiser Permanente Hawaii is a clinical research site located in Honolulu, Hawaii, United States 96819.
Crixeo Health Trust Score: 80/100 (GOOD). This profile has not yet been claimed by the site owner.
Kaiser Permanente Hawaii has participated in 12 clinical trials with 3 currently active.
Therapeutic areas: NSCLC, HER2-positive Breast Cancer, Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive.
Sponsors: Eikon Therapeutics, Seagen, a wholly owned subsidiary of Pfizer, Pfizer.
Trust Score: 80/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Kaiser Permanente Hawaii has a Crixeo Trust Score of 80/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Kaiser Permanente Hawaii has 12 clinical trials on record, with 3 currently active. Their work covers NSCLC, HER2-positive Breast Cancer, Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive.
Yes — Kaiser Permanente Hawaii holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.